**Name(s)**  
Anin Sayana  

**Project Number**  
J1724  

**Project Title**  
A Novel Configuration of Carbon Nanotubes to Selectively Target Chemotherapy-Resistant Cancer Stem Cells  

**Abstract**  
Current chemotherapy methods to treat cancer do not eradicate all of the cancer cells, and a relapse of the tumor often occurs because of a subpopulation of self-renewing and self-differentiating cells called cancer stem cells (CSCs). CSCs express the surface marker CD133 and the membrane transporter protein ABCG2, which induces chemotherapy resistance. I hypothesized that chemotherapy drugs can be made more effective in targeting CSCs by loading the chemotherapy drug and the ABCG2 inhibitor Imatinib into a multi-wall carbon nanotube (CNT) conjugated with the CSC-specific anti-CD133 antibody.

**Methods/Materials**  
L1210 Leukemia Cells were grown in 30 flasks for three weeks in DMEM+FBS+Penicillin/Streptomycin. A FACS flow cytometry test was conducted, in which $1 \times 10^4$ cells were conjugated with the FITC anti-CD133 antibody and analyzed to determine the percentage of CD133-expressing cancer stem cells. Additionally, $2.5 \times 10^4$ cells were tested for chemotherapy resistance, a property of CSCs, using ethidium bromide. To test for destruction of CSCs, CNTs were conjugated with the anti-CD133 antibody, Imatinib (IM), and ethidium bromide (EB). Cells were treated with this configuration and 10 combinations of EB, IM, CNT+Anti-CD133 Antibody, using $2.5 \times 10^4$ CSCs per test. Each test was repeated four times, for a total of 40 tests. Healthy cells with the CNT combination were tested for cell viability. Finally, a SEM analysis and student t-test were conducted.

**Results**  
CSCs identified by flow cytometry expressed chemotherapy-resistance, as < 1% of the cells were nonviable when treated with EB and EB+IM. For CSCs treated with CNT+Anti-CD133+EB+IM, > 99% of the CD133+ expressing CSCs were nonviable, while healthy cells were viable. The nonviability rate of CNT+Anti-CD133+EB was 7.5%, Imatinib alone was 5.5%, and CNT+IM+Anti-CD133 was 5.75%. The SEM images proved the binding of the CNTs to the cells. A p-value of p < 0.001 from the student t-test showed an extremely significant statistical difference between the values.

**Conclusions/Discussion**  
The FACS and the chemotherapy resistance tests identified the CD133+ cells and proved them to be chemotherapy resistant, and the novel CNT configuration successfully destroyed the cancer stem cells. The incorporation of the Anti-CD133 antibody, ABCG2 inhibitor imatinib, and chemotherapy drug in carbon nanotubes shows promise for the treatment of conventional-cancer-therapy-resistant CSCs.

**Summary Statement**  
I identified a population of chemotherapy-resistant CD133+ cancer stem cells, created a carbon nanotube configuration to selectively target the CSCs, and tested this combination's effect on cancer stem cell viability.

**Help Received**  
Dr. Ali Haghihigi for advice and supervision of use of lab equipment; Dr. Megan Suhoski from Stanford University for advice on initial research; The Nanomaterials and Nanostructures Laboratory for use of the SEM; Dr. Han-Shui Hsu for providing research articles; my science teacher and parents for support.